A pilot study of prostate-specific membrane antigen (PSMA) dynamics in men undergoing treatment for advanced prostate cancer.

Channing J PallerDanilo PianaJames R EshlemanStacy RielSamuel R DenmeadePedro Isaacsson VelhoSteven P RoweMartin G PomperEmmanuel S AntonarakisJun LuoMario A Eisenberger

Published in: The Prostate (2019)

PSMA expression in CTCs is a dynamic marker. PSMA transcript declines appear to be associated with concurrent decreases in serum PSA. Sequential CTC sampling could provide a noninvasive response assessment to systemic treatment for mCRPC.

Keyphrases

prostate cancer
pet ct
pet imaging
radical prostatectomy
circulating tumor cells
poor prognosis
combination therapy
locally advanced
rectal cancer
benign prostatic hyperplasia
smoking cessation
single cell